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Abstract
Background: Recent sepsis guidelines have focused on the early identification and risk stratification of patients on
presentation. Obesity is associated with alterations in multiple inflammatory regulators similar to changes seen in
sepsis, suggesting a potential interaction between the presence of obesity and the severity of illness in sepsis.
Methods: We performed a retrospective chart review of patients admitted with a primary billing diagnosis of sepsis
at a single United States university hospital from 2007 to 2010. Seven hundred and ninety-two charts were
identified meeting inclusion criteria. Obesity was defined as a body mass index (BMI)≥ 30 kg/m2. The data
recorded included age, race, sex, vital signs, laboratory values, length of stay, comorbidities, weight, height, and
survival to discharge. A modified APACHE II score was calculated to estimate disease severity. The primary outcome
variable was inpatient mortality.
Results: Survivors had higher average BMI than nonsurvivors (27.6 vs. 26.3 kg/m2, p = 0.03) in unadjusted analysis.
Severity of illness and comorbid conditions including cancer were similar across BMI categories. Increased incidence
of diabetes mellitus type 2 was associated with increasing BMI (p < 0.01) and was associated with decreased
mortality, with an odds ratio of 0.53 compared with nondiabetic patients. After adjusting for age, gender, race,
severity of illness, length of stay, and comorbid conditions, the trend of decreased mortality for increased BMI was
no longer statistically significant, however diabetes continued to be strongly protective (odds ratio 0.52, p = 0.03).
Conclusions: This retrospective analysis suggests obesity may be protective against mortality in septic inpatients.
The protective effect of obesity may be dependent on diabetes, possibly through an unidentified hormonal
intermediary. Further prospective studies are necessary to elaborate the specific mechanism of this protective effect.
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Background
Despite recent improvements in identification and treat-
ment, sepsis remains a common, costly, and deadly con-
dition at U.S. hospitals. With an annual case rate of 3.0
per 1000 population, sepsis costs the U.S. healthcare sys-
tem an estimated $16.7 billion annually [1]. Additionally,
the mortality rate from severe sepsis has risen from 66.8
to 132 per 100,000 population per year between 1993
and 2003 [2]. Despite this increase, earlier recognition
and more aggressive treatment of severe sepsis within
the first hours of hospital arrival have decreased mortal-
ity per admission from 45.8 to 37.8% [2]. These findings
underscore the need for rapid identification of patients
with severe sepsis and poor prognosis in order to initiate
aggressive treatment within the first minutes of hospital
arrival.
The obese population may exhibit an altered response to
the acute inflammatory stressor of sepsis [3]. The patho-
logic response in sepsis is mediated through inflammatory
cytokines [4], and comparable changes are seen in other-
wise healthy patients with obesity [5-8]. Murine models
of sepsis have demonstrated increased mortality in obese
mice [9,10]. Recent investigations into the alterations in
response to sepsis in these animal models have focused
on hormonal mediators, including leptin and adiponectin
[11-13]. Serum levels of these hormones are also altered
in obese humans [14,15]. Furthermore, alterations in serum
leptin [16] and adiponectin [17] have correlated with
human survival in sepsis, although these relationships
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are complex and the investigations have been small.
These findings suggest a potential correlation between
sepsis mortality and obesity, and previous investigators
have noted obese patients have impaired immune re-
sponses to viral and bacterial pathogens [18].
Despite this potential link, relatively few clinical studies
have looked at the clinical interaction. A recent study
of bacteremic patients by Huttunen et al. [19] found in-
creased mortality in obese patients, but only 10 of 19
deceased patients had recorded body mass index (BMI)
data. Wurzinger et al. [20] found a correlation between
increasing BMI and decreased mortality for adult pa-
tients with septic shock, but morbid obesity was under-
represented in their sample (only 9 of 303 subjects had
BMI > 40 kg/m2). In contrast, Nasraway et al. [21] found
morbid obesity was significantly associated with death
only in the subset of prolonged stay patients (≥ 4 days),
but the study followed all surgical intensive care unit ad-
missions and did not report specific information about
sepsis. Dossett et al. [22] demonstrated increased survival
in morbidly obese patients (87%) compared with patients
with normal (84%) or underweight (78%) BMIs in two
surgical intensive care units. However the trend failed
to reach statistical significance. A recent review of the
impact of obesity on pulmonary infections found evi-
dence of increased incidence, severity, and death as a re-
sult of the H1N1 influenza pandemic of 2009 among
obese patients, but found conflicting results for mortal-
ity in bacterial pneumonia [23]. Due to the limitations
of currently published research there have been several
recent calls for further study to clarify the relationship
between obesity and mortality in sepsis [23-26]. The
objective of this study was to determine the association
between BMI and survival in patients admitted with a
diagnosis of sepsis. Based on the limited clinical data,
we predicted increased survival in obese and morbidly
obese patients.
Methods
The study was conducted at Penn State Milton S. Hershey
Medical Center, an integrated health system including a
473-bed academic medical center, an emergency depart-
ment with greater than 50,000 annual visits, and an
outpatient medical group with over 800,000 visits. A
retrospective chart review was performed on all adult
patients (≥ 18 years old) who presented to the emer-
gency department or were directly admitted to the hos-
pital with a primary billing diagnosis of sepsis (ICD-9
codes 38.0-38.9) between July 1, 2007 and June 30, 2010.
Patients without a documented height and weight (to
calculate BMI) were excluded from analysis. The patients’
charts were accessed using a report writing tool that
allowed automated extraction of study data from the
clinical database. Data points that could not be collected
via the clinical database were gathered through manual
chart review by a collaborator not directly involved in
data analysis. The data recorded included date and time
of patient arrival, age, race, sex, vital signs, laboratory
values, length of stay, comorbidities, weight, height, and
survival to discharge. The primary outcome variable was
inpatient mortality. This study was approved by the
Penn State College of Medicine Institutional Review Board.
The covariates in this study included BMI, age, race
(categorized as white, black, or other), gender, length of
stay, comorbid conditions (diabetes mellitus, neutropenia,
cancer, liver disease, cardiovascular disease, chronic ob-
structive pulmonary disease, renal disease, and immuno-
suppression),and a modified APACHE II score. Modified
APACHE II score was used as a measure of disease se-
verity and was based on patient vital signs, mean arterial
pressure, comprehensive metabolic panel, oxygenation
(based on oxygen saturation and oxygen therapy), arterial
pH, mental status change on admission, age, and presence
of chronic diseases [27]. The first recorded value within
twenty-four hours was used for each category of the
APACHE II. The Glasgow Coma Score used in the
APACHE II scoring system was approximated using men-
tal status on admission. No mental status change received
a score of 15/15, a mild change received a score of 13, and
severe change received a score of 10. Similar electronic
approaches have been shown to correlate strongly with
APACHE II scores [27]. Diagnoses of diabetes and neutro-
penia were determined based upon ICD-9 codes. All other
comorbid conditions were determined from admission
documentation.
Weight category was determined by calculating body
mass index (BMI) Body Mass Index was divided into
five categories (Underweight: < 18.5, Normal: 18.5-24.9,
Overweight: 25.0-29.9, Obese: 30.0-39.9, Morbidly obese:
40.0-49.9 kg/m2). Patients with BMI greater than 50 or
missing BMI were excluded as outliers (n = 15, range
50.4 to 93.9 kg/m2). Categorical variables were summa-
rized with frequencies and percentages while continu-
ous variables were summarized with means, standard
deviations, medians, and quartiles. The distribution of
continuous variables was checked using box plots, his-
tograms, and normal probability plots. It was found that
length of stay had a skewed distribution, with a minority
of patients having a very long length of stay. Therefore,
a log transformation was applied to this variable to allow for
a comparison by BMI categories with parametric methods.
Comparisons between BMI categories were made for
continuous variables such as age, length of stay, and
APACHE II score using an Analysis of Variance (ANOVA)
with the differences quantified by means (Table 1). Com-
parisons between BMI categories were made for categorical
variables using two approaches, a Chi-square test for
variables like gender and race and a Cochran-Armitage
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Table 1 Variables by body mass index categories
Variable All Body mass index P-value
Underweight Normal weight Overweight Obese Morbidly obese
Subjects, N (%) 792 (100) 49 (6) 261 (33) 249 (31) 187 (24) 46 (6)
Age +
Years 61.9 ± 17.2 60.3 ± 22.9 61.2 ± 19.2 64.2 ± 16.0 60.8 ± 14.2 60.2 ± 13.7 0.17
Gender *
Female 362 (46) 32 106 105 85 34 < 0.01
Male 430 (54) 17 155 144 102 12
Race *
White 726 (92) 43 247 221 174 41 0.03
Black 41 (5) 2 11 14 9 5
Other 24 (3) 4 3 13 4 0
Length of stay †
Days 9.1 ± 8.2 8.1 ± 7.2 9.3 ± 8.5 8.8 ± 7.8 9.0 ± 8.1 10.2 ± 9.6 0.64
APACHE II Score +
Points 15.5 ± 5.9 16.2 ± 6.6 15.4 ± 5.8 15.6 ± 5.8 15.9 ± 6.1 14.2 ± 5.6 0.42
Mortality ‡
Yes 129 (16) 12 46 40 25 6 0.06
No 663 (84) 37 215 209 162 40
Diabetes ‡
Yes 190 (24) 10 17 21 35 48 < 0.01
No 602 (76) 90 83 79 75 52
Cancer ‡
Yes 356 (45) 33 46 50 44 24 0.40
No 436 (55) 67 54 50 56 76
Neutropenia ‡
Yes 44 (6) 2 5 8 4 9 0.50
No 748 (94) 98 95 92 96 91
Liver ‡
Yes 43 (5) 4 5 6 4 9 0.61
No 749 (95) 96 95 94 96 91
Cardiovascular Disease ‡
Yes 188 (24) 24 21 24 25 28 0.33
No 604 (76) 76 79 76 75 72
COPD ‡
Yes 80 (10) 8 7 10 16 9 0.04
No 712 (90) 92 93 90 84 91
Renal ‡
Yes 30 (4) 4 6 3 2 4 0.14
No 762 (96) 96 94 97 98 96
Immunosuppression ‡
Yes 78 (10) 16 10 8 11 7 0.29
No 714 (90) 84 90 92 89 93
*Categorical data presented as N (%) or % and analyzed with Pearson Chi-square test (Exact test if necessary).
+Numeric data presented as Mean ± SD and analyzed with Analysis of Variance.
†Numeric data presented as Mean ± SD, log-transformed for analysis by Analysis of Variance.
‡Categorical data presented as N (%) or % and analyzed with Cochran-Armitage Trend test.
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Trend test for variables like mortality, diabetes, and other
comorbidities with differences quantified by percentages
(Table 1). Comparisons by mortality of this same set of
variables including BMI, as a continuous variable, were
made using logistic regression and were quantified with
odds ratios (Table 2). All variables were then included
as covariates with BMI in a multivariable logistic regres-
sion model which adjusts each variable and its accom-
panying odds ratios for all of the other variables in the
model (Table 2). Covariates were analyzed for multi-
collinearity using the variance inflation factor, and the
model fit was checked with the Hosmer and Lemeshow
Goodness-of-Fit test. All analyses were conducted using
SAS Software version 9.3 (SAS Institute, Cary, NC).
Results
Chart review identified 845 patients with a presenting
diagnosis of sepsis over the specified time period. Of
these patients, 792 met inclusion and exclusion criteria.
There were 129 inpatient deaths in the study population.
Demographics of the cohort by BMI category are sum-
marized in Table 1. Six percent of study participants
were morbidly obese, 24% were obese and 31% were
overweight, comparable to recent national statistics [28].
Septic patients who were underweight or morbidly obese
were significantly more likely to be female. As expected,
the prevalence of diabetes mellitus increased significantly
with increasing BMI. There were also statistically signifi-
cant differences in race across BMI categories. Length of
stay (average 6.5 days) and disease severity, measured by
modified APACHE II score, were not significantly associ-
ated with alterations in BMI.
Using a Cochran-Armitage test, increased mortality
trended towards a lower BMI category, although the trend
failed to reach statistical significance (p = 0.06). Using nor-
mal weight (BMI 18.5-24.9 kg/m2) as a reference group
in logistic regression, the odds ratio for mortality was
1.5 (95% CI 0.67-6.3) for underweight patients and 0.7
(95% CI 0.12 – 4.2) for those with morbid obesity (p = 0.19).
This clinically significant variation in mortality with re-
spect to BMI reached statistical significance in the analysis
using BMI as a continuous variable. Survivors had a BMI
of 27.6 kg/m2, compared with 26.3 kg/m2 among non-
survivors (p = 0.03).
This difference in mortality was not explained by dif-
ferences in comorbid conditions. Comorbidities across
BMI categories are summarized in Table 1. There were
similar prevalences of cancer and neutropenia between
BMI categories. Of the comorbid conditions examined for
this study, only chronic obstructive pulmonary disease
(COPD, p = 0.04) and diabetes mellitus (p < 0.01) were
found to be associated with BMI category. Table 2 sum-
marizes the relationships between comorbid conditions
and inpatient mortality for this cohort. The odds ratio for
mortality comparing patients with and without COPD
was 1.10 (95% CI 0.6 to 2.03, p = 0.76), failing to reach
statistical significance. Pre-existing liver and cardiovas-
cular diseases were found to significantly predispose to
inpatient mortality but did not correlate with BMI. Dia-
betes mellitus was found to be significantly protective
against death, with an odds ratio for mortality of 0.53
(95% CI 0.32-0.88, p = 0.01). Due to the high mortality
and low incidence of diabetes mellitus in patients with
low BMI, the analysis was repeated excluding under-
weight (BMI < 18.5 kg/m2). The results were unchanged,
with an OR for mortality of 0.54 (95% CI 0.32-0.91,
p = 0.02).
To better characterize the correlation between obesity
and survival, multivariate analysis was performed using
the tabulated demographic variables and comorbid condi-
tions (Table 2). Race and COPD, which had been found
to correlate with BMI, were not associated with signifi-
cant changes in mortality. Increasing age (per 5 year
increments) and increasing APACHE II score (per 1
point) were both found to be independent risk factors
for increased mortality (adjusted OR 1.12 and 1.14 re-
spectively, p < 0.01). When adjusted for the presence of
diabetes, BMI trended towards protection from inpatient
mortality (OR 0.90 for 5 kg/m2 increase, p = 0.19) but
failed to reach statistical significance. Diabetes mellitus
remained strongly protective with OR 0.52 (95% CI 0.29-
0.93, p = 0.03) despite adjustment for other comorbid
conditions. No other comorbidity was found to have a
statistically significant relationship with inpatient survival.
Discussion
Obesity, including morbid obesity, was protective for in-
patient sepsis mortality within this cohort, but the pro-
tection appears to have been due to the presence of
comorbid insulin resistance and diabetes. This finding,
although similar to the results of previous clinical trials
[20-22] is not easily explained through our current
understanding of the physiology of obesity, diabetes,
and sepsis. One possible mediator of this protection is
leptin, a hormone highly elevated in human obesity [15].
Leptin-knockout mice have excess weight gain and have
been used as an in vivo model of human obesity. When
exposed to a septic challenge, mice incapable of secreting
leptin have increased serum levels of TNF- α and IL-6 as
well as increased mortality [9,10,29]. This increase in mor-
tality is partially reversed by treatment with exogenous
leptin [9,10]. Leptin has also been shown to be independ-
ently elevated by critical illness in non-obese humans [16]
and to reduce endotoxin-induced TNF-α production [29].
Diabetes mellitus has been associated with increased
incidence of infectious disease and increased infectious
disease mortality [30-32], however in this cohort the
presence of diabetes was associated with markedly reduced
Kuperman et al. BMC Infectious Diseases 2013, 13:377 Page 4 of 8
http://www.biomedcentral.com/1471-2334/13/377
Table 2 Variables by mortality**
Variable (N = 792) Mortality Unadjusted
odds ratio (95% CI)
Adjusted
odds ratio (95% CI)
Adjusted
P-value
Yes (%) No (%)
Age* (OR per 5 years)
Years 69.8 ± 14.3 60.4 ± 17.3 1.04 (1.02, 1.05) 1.12 (1.04, 1.21) < 0.01
Gender
Female 17 83 1.04 (0.71, 1.52) 0.96 (0.63, 1.46) 0.85
Male 16 84 1.0 (reference) 1.0 (reference)
Race
White 17 83 1.0 (reference) 1.0 (reference)
Black 12 88 0.69 (0.21, 1.83) 1.09 (0.39, 3.08) 0.87
Other 12 88 0.71 (0.13, 2.45) 0.92 (0.24, 3.56) 0.90
Length of stay* (OR per 1 day)
Days 8.6 ± 9.5 9.1 ± 7.9 0.99 (0.97, 1.02 0.99 (0.96, 1.02) 0.65
APACHE II score* (OR per 1 point)
Points 19.9 ± 6.7 14.7 ± 5.4 1.16 (1.12, 1.20) 1.14 (1.10, 1.19) < 0.01
Body Mass Index*, kg/m2
kg/m2 26.3 ± 6.8 27.6 ± 6.7 0.97 (0.94, 1.0) 0.90 (0.76, 1.06) 0.19
Diabetes
Yes 11 89 0.53 (0.32, 0.88) 0.52 (0.29, 0.93) 0.03
No 18 82 1.0 (reference) 1.0 (reference)
Cancer
Yes 16 84 0.96 (0.66, 1.41) 1.03 (0.64, 1.65) 0.90
No 17 83 1.0 (reference) 1.0 (reference)
Neutropenia
Yes 9 91 0.50 (0.18, 1.42) 0.40 (0.13, 1.24) 0.11
No 17 83 1.0 (reference) 1.0 (reference)
Liver
Yes 28 72 2.09 (1.04, 4.19) 1.68 (0.75, 3.78) 0.21
No 16 84 1.0 (reference) 1.0 (reference)
Cardiovascular Disease
Yes 22 78 1.71 (1.13, 2.58) 0.91 (0.55, 1.52) 0.73
No 14 86 1.0 (reference) 1.0 (reference)
COPD
Yes 18 82 1.10 (0.60, 2.03) 0.79 (0.40, 1.54) 0.48
No 16 84 1.0 (reference) 1.0 (reference)
Renal
Yes 17 83 1.03 (0.30, 2.81) 0.96 (0.32, 2.87) 0.94
No 16 84 1.0 (reference) 1.0 (reference)
Immunosuppression
Yes 15 85 0.93 (0.49, 1.77) 0.79 (0.39, 1.63) 0.53
No 16 84 1.0 (reference) 1.0 (reference)
*Categorical data presented as Percent, Numeric data presented as Mean ± SD.
**Logistic regression used for all analyses, Adjusted odds ratios are adjusted for all variables in the table.
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mortality. A previous study by Whitcomb et al. [33] found
a similar trend towards decreased mortality for septic
patients with a previous diagnosis of diabetes despite
increased mortality for patients with newly-diagnosed
hyperglycemia. Other previous attempts to prove an as-
sociation between diabetes mellitus and sepsis mortality
have had equivocal results. Two studies observed no dif-
ference in mortality between diabetic and nondiabetic
patients with sepsis despite diabetic patients having in-
creased comorbidities at admission [34,35]. Diabetes
mellitus has also been associated with decreased acute
lung injury in severe sepsis [36]. This suggests diabetic
patients may have increased incidence of sepsis or present
with more severe illness, but are less likely to die from an
individual episode of sepsis when controlling for disease
severity. The mechanism for this protection is unclear,
and may be due either to the pathology and hormonal
changes of diabetes or the medical therapy used to treat it.
Animal models attempting to separate the effects of
diabetes and obesity in sepsis response have been lim-
ited. The Akita mouse model develops severe diabetes
mellitus through a mutation in the Ins2 gene leading to
accumulation of proinsulin and β-cell dysfunction [37].
In contrast to the results of this study, Akita mice had
increased mortality and decreased pro-inflammatory cy-
tokines compared with wild type controls when under
septic challenge [38]. However, the diabetes in these mice
was untreated and it is unclear if the results can be com-
pared with this human population where both diabetes
and sepsis were treated aggressively. Diabetes mellitus
can also be induced in mice by exposure to streptozotocin, an
antibiotic with β-cell toxicity [39]. Mice with streptozotocin-
induced diabetes exhibit increased mortality and decreased
bacterial clearance compared with controls after receiving
a septic challenge, which partially corrected after being
treated with insulin [40]. However, both models would
exhibit insulin deficiency, and would have significantly
different adipokine levels in comparison with the dia-
betic patients in this study population.
Previous efforts to link tight glycemic control with
sepsis survival in humans have been complicated by high
rates of hypoglycemia leading to early termination [41].
If endocrine mediators are responsible, pharmacologic
modification of serum hormone levels may alter sepsis
mortality. For example, increased serum levels of adiponectin
are associated with sepsis survival, and in animal models
these levels are increased by exposure to rosiglitazone (an
oral medication used to treat diabetes) resulting in im-
proved survival with a septic challenge [42]. Unfortunately
an accurate record of the patients’ home medications was
not contained within the electronic medical record for this
cohort. Further elucidation of the mechanism of protec-
tion may lead to improved outcomes not only in the dia-
betic patients but also in the nondiabetic, nonobese
population through pharmacologic manipulation of in-
flammatory regulation.
The underweight (BMI < 18.5 kg/m2) population had
increased inpatient mortality compared with the overall
cohort (24% vs. 16%). Previous investigators have found
increased incidence of sepsis and severe sepsis in the
underweight population [43] as well as higher disease
severity at admission [44]. The trend towards worsened
survival in this cohort does not appear to be due to in-
creased incidence of comorbid conditions including can-
cer, renal disease, or liver disease as these conditions
were not present at higher rates in patients who were
underweight. Whether the observed statistical trend was
due to loss of physiologic reserve, the presence of other
comorbidities not captured on our retrospective review,
or the continuation of physiologic processes protective in
obese patients cannot be ascertained without further
prospective investigation.
Conclusions
This study is one of the largest examining the relationship
between BMI, diabetes, sepsis and mortality. Strengths
of this study include the large cohort size and the use
of an electronic medical record to capture a nearly
complete database of the patients selected for study in-
clusion. The multivariate analysis including common
comorbid conditions, and the strength of the relation-
ship between diabetes and decreased mortality was
robust even after adjusting for numerous covariates.
There were several limitations to this study. The re-
sults of this single-center study will need to be docu-
mented at other institutions to ensure generalizability.
Due to the limitations of the electronic medical record,
BMI was used to define obesity. Additionally, we limited
our analysis to patients with a BMI < 50 kg/m2, as the
small number of patients (n = 15) above this BMI there
was insufficient statistical power to draw meaningful
conclusions. Therefore, these results cannot be extrapo-
lated to individuals above this BMI range. As a retro-
spective chart review, we were limited to information
documented in the electronic medical record. This im-
peded analysis of glycemic control and follow-up of pa-
tients beyond hospital discharge. Similarly, the etiology
of sepsis (pneumonia, bloodstream infection, urinary
infection) could not be determined from this data set.
It also prevented collection of additional data, such as
serum concentrations of leptin or adiponectin, which
may help clarify the underlying mechanism of the pro-
tection seen in diabetic patients. Further, there was no
standardization of treatment for diabetic or hypergly-
cemic patients in this cohort, and information was un-
available about outpatient pharmacotherapies, including
oral hypoglycemic agents taken by patients prior to
hospital arrival. Although this study analyzed diabetes
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mellitus as a categorical variable, in reality diabetes
represents a spectrum of disease with variable insulin
resistance and blood glucose levels. Further investiga-
tions will be required to fully understand this trend.
This study adds to the growing body of evidence that
obesity is not universally detrimental to survival, and
may be a clinically useful model for underlying protective
processes. Although the mechanism of this protection is
not understood, it appears to be related to insulin resist-
ance, possibly through endocrine mediators. Given the
protective effect against mortality identified in patients
with diabetes mellitus, insulin and glucose levels may also
strongly affect the immune response. Future prospective
studies will be needed to better define this relationship.
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